NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Pablo Corral: A True Game Changer in Lipid Management
Pablo Corral/LinkedIn
Nov 9, 2025, 01:51

Pablo Corral: A True Game Changer in Lipid Management

Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:

”AHA 2025 | CORALreef Lipids Trial

A true game changer in lipid management.

Enliciditide (MK-0616) – the first oral PCSK9 inhibitor – achieved a 57% LDL-C reduction at week 24 and – 50% sustained at week 52 vs placebo (p<0.001).

  • Phase 3 trial, 2,912 patients with ASCVD or at high risk, across 14 countries, with excellent safety profile.
  • Takeaway: efficacy and safety comparable to injectable PCSK9 inhibitors — but in a once-daily oral tablet.
  • A new era in PCSK9 inhibition and cardiovascular prevention.”

Pablo Corral

Stay updated with Hemostasis Today.

AHA Cardiology Cardiovascular Prevention Enliciditide Health Hematology Hemostasis Today Lipid Management Medicine Pablo Corral PCSK9 inhibitor
NewsFeed